Board summary
Key figures
97,870
Registered population
61.3% aged 18–64
18.6%
Aged 65+
ICB 19.0% · England 17.9%
5.8%
Ethnic minority (non-White)
2.8% Asian · England 9.6%
57.5%
In IMD quintile 1
ICB 31.9% · England 21.0%
~45,090
Core20 residents (est.)
Resident basis; registered basis ~58,354 · see page 3
16,442
Hypertension register
+5.26% in 3 yrs · England +5.60%
1,432
SMI register
35.8% of Wirral (LAD)'s
3,170
COPD register
Reviews +2.67% in 3 yrs
Forecast to 2030
18,664
Hypertension patients, 2030
+2,222 on today
76.2%
QRISK ≥20% on statins, 2030
+3.40pp over 3 yrs
4.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews leave 2,514 patients unreviewed.
Annual asthma review coverage is 65.0% (England 65.7%) across 7,188 registered patients, which may reflect recall gaps to verify via practice audit.
Age-five MMR2 coverage misses 95.0% target.
Age-five MMR2 coverage is 7.4 pp below the 95.0% target and 4.9 pp below MMR1 (92.5%), which could reflect second-dose recall gaps.
High-risk lipid therapy exceeds England benchmark.
Lipid-lowering therapy in patients with QRISK ≥ 20% reaches 68.9% against 65.8% in Wirral, 63.2% in the ICB, and 63.6% in England.
Population, age and ethnicity
Birkenhead PCN serves 97,870 patients with 18.6% aged 65+ alongside 2,168 care beds
Birkenhead PCN registers 97,870 patients. Older people aged 65+ comprise 18.6% of the list (England 17.9%; Wirral 20.7%; ICB 19.0%), while children aged 0-17 make up 20.1% (England 19.6%; Wirral 19.0%; ICB 19.2%). Projected list growth to 2030 is 1.3% (England 2.3%; Wirral 1.2%; ICB 2.3%) under an unverified forecast methodology. Census residents are 94.2% White (England 81.1%; Wirral 95.2%; ICB 93.0%) and 5.8% ethnic minority, with Asian residents at 2.8% (England 9.6%; Wirral 2.3%; ICB 2.8%). Ethnicity reflects associated area residents, not registered patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Wirral (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wirral LA) | 1,517 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.0% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wirral LA) | 753 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wirral LA) | 25.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 57.5% of registrations, spanning a 100 pp practice range
Birkenhead PCN has 57.5% of registered patients in the Core20 cohort, well above Wirral (34.8%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 3.5 against Wirral's 5.2 and England's 5.5. Across practices, Core20 share spans a 100 pp range, from 0.0% at Holmlands Med Ctr to 100.0% at Hamilton Med Ctr. While smaller practices reach 100.0% concentration, patient volume concentrates in St Catherine's Surgery (11,263) and Miriam Primary Care Group (10,018). Reconciling the 58,354 practice sum with the 45,090 resident estimate must precede outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,432
SMI register
1.45% recorded prevalence
875
Learning disability register
0.89% recorded prevalence
69
Care homes, 2,168 beds
In the PCN catchment
10.9%
Provide unpaid care
Wirral (LAD), Census 2021
Birkenhead PCN records 1,432 patients on its severe mental illness register (1.4%; England 1.0%; Wirral 1.2%; ICB 1.1%) and 875 on its learning disability register (0.9%; England 0.6%; Wirral 0.8%; ICB 0.6%). The PCN catchment includes 2,168 beds across 69 care homes. Recorded prevalence above England is consistent with substantial review demand, though care beds do not establish resident registrations.
Severe mental illness: physical health checks
Birkenhead PCN records 1.4% SMI prevalence. Annual checks lag England: BMI recording is 77.4% (England 82.1%), BP checks are 82.0% (England 83.4%), and alcohol recording fell 1.5 pp over three years (England +5.4 pp) to 78.7%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
16,442
Hypertension register
+5.26%
Register growth, 3 yrs
Wirral (LAD) +6.35% · England +5.60%
+1.31pp
BP control, under 80
≤140/90 · −0.64pp aged 80+
+2,222
More patients by 2030
Forecast 18,664 (18.49%)
Hypertension case-finding and control
Hypertension recorded prevalence is 16.7% (16,442 patients), above England (15.2%) and in line with the ICB (16.8%), though below Wirral (18.0%). Hypertensive patients with a recent blood pressure check reach 89.3% (England 90.0%), having fallen 0.3% over three years (England +3.6%; ICB +2.6%). Overall blood pressure control to target is 68.2% (England 70.3%), with control under age 80 at 65.9% (England 67.8%). Lagging monitoring and control relative to England suggest active recall and titration could be audited to improve control.
Lipids and statins
Lipid-lowering therapy reaches 68.9% in patients with QRISK ≥ 20%, exceeding England (63.6%) and Wirral (65.8%), alongside 87.5% statin coverage in diabetes with cardiovascular disease (England 84.4%). Higher lipid coverage than England shows strong secondary and primary prevention reach that PCN practices should sustain.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 203,654 | £2.00 | £1.71 | £1.86 | £407,308 |
| Cardiovascular (all), 2025 | 270,603 | £5.03 | £4.37 | £3.33 | £1,361,133 |
In 2026, lipid-regulating drugs cost £2.00 per item across 203,654 items (£407,308 spend), compared to £1.86 in England and £1.71 in the ICB. This represents £28,512 more than at England's unit cost. Unit cost differences do not reflect clinical efficiency, but a formulary review could test whether cost-effective statin choices are optimised.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.81%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.89%
Asthma prevalence, PCN 3-yr % change
Paediatric asthma prescribing reaches 2,961 items per 1,000 aged 5-19 (England 1,488; Wirral 2,621; ICB 2,310). Asthma prevalence is 7.8% (England 6.6%), while annual review coverage of 65.0% (England 65.7%) leaves an estimated scale gap of 2,514 unreviewed patients. COPD prevalence is 3.2% (England 1.9%), with 3-year prevalence falling 0.4% (England +2.6%) and annual reviews at 74.3% (England 76.4%). Review patterns could reflect unverified recall shortfalls to audit locally.
Cancer register and children's immunisation
Cancer prevalence is 4.0% (England 3.8%; Wirral 4.8%). In Q1 2025/26, childhood immunisations missed the 95.0% standard across cohorts. Dose 1 MMR at 24 months reached 85.0% (England 88.3%). By age 5, MMR dose 2 reached 87.6%, below dose 1 (92.5%) by 4.9 pp, while 4-in-1 booster coverage was 83.8% (England 80.9%). This same-cohort gap could reflect delayed scheduling, which local audit would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB, 55.5% of staged cancers were diagnosed at stage 1 or 2 in 2022 (up 2.6 pp from 52.8% in 2013), sitting 19.5 pp below the 75.0% national ambition. Sizing this gap indicates about 2,640 extra early diagnoses are required annually, where known stage share sits 2.2 pp below the 75.0% national ambition. Locally, Birkenhead PCN records 64.7% breast screening coverage (Wirral 72.6%; England 69.9%) and 68.0% cervical screening coverage (Wirral 71.5%; England 66.8%), trailing at Whetstone Lane Med Ctr (57.0%), Hamilton Med Ctr (58.7%), and Gladstone Med Ctr (60.3%). Lower screening coverage may delay early detection across local practices.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Wirral University Teaching Hospital NHS Foundation Trust, 62-day cancer referral to treatment was 77.647% (standard 85.0%), 28-day faster diagnosis was 74.7058% (standard 75.0%), and 31-day combined treatment was 92.5266% (standard 96.0%). Across NHS Cheshire and Merseyside Integrated Care Board, 62-day performance was 76.232% (standard 85.0%), 28-day faster diagnosis was 77.2451% (standard 75.0%), and 31-day combined treatment was 95.7087% (standard 96.0%). These trust and ICB cancer waiting times describe wider secondary care performance rather than PCN delivery.
| Pathways within standard (%) | Wirral | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.71 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.53 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.65 | 73.26 | 77.96 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wirral | Liverpool | Mersey and West Lancashire | England |
|---|---|---|---|---|
| MRI | 1.54 | 6.42 | 14.04 | 21.40 |
| CT | 1.55 | 0.71 | 13.08 | 9.92 |
| Echocardiography | 5.07 | 12.55 | 34.88 | 28.48 |
| Colonoscopy | 32.81 | 33.14 | 18.04 | 30.83 |
| Gastroscopy | 17.73 | 44.99 | 18.17 | 29.02 |
| All 15 DM01 tests | 5.02 | 11.50 | 21.17 | 23.14 |
| Community services activity | Wirral residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 58,870 | 541,280 |
| Referrals | 13,315 | 97,150 |
| Patients with a contact | 17,205 | 146,240 |
Community services (residents of Wirral), Jun 2026 (provisional). In Wirral, 66.1% of community service contacts were with adults aged 65 and over (38,930 of 58,870 contacts in provisional Jun 2026 data). Activity is captured only for borough residents, with no PCN or provider breakdown. These borough figures describe wider system activity and cannot be extrapolated to PCN delivery.
Practice variation and patient experience
Phone access spans 48.0 pp while vaccination achievement varies by 84.4 pp
In 2025/26, the England benchmark for QOF overall achievement was 92.5%. Devaney Med Ctr achieved 76.6% overall achievement, while Hamilton Med Ctr achieved 99.9%. In the QOF vaccination and immunisation domain, the England benchmark was 55.2%. Gladstone Med Ctr achieved 15.6% domain achievement, whereas Hamilton Med Ctr achieved 100.0%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Villa | 121 | 3.3 | 77.3% | 67.1% | 97.4% |
| Kings Lane | 130 | 0.0 | 58.2% | 62.3% | 94.5% |
| Hamilton Med Ctr | 109 | 100.0 | 82.3% | 72.6% | 91.0% |
| Cavendish | 97 | 88.9 | 70.4% | 74.1% | 90.6% |
| Vittoria Med Ctr K | 100 | 100.0 | 89.9% | 61.0% | 89.6% |
| Church Road | 122 | 0.0 | 87.8% | 75.3% | 89.1% |
| Holmlands Med Ctr | 98 | 0.0 | 84.6% | 77.5% | 88.6% |
| Teehey Lane | 104 | 0.0 | 83.7% | 80.0% | 84.9% |
| Miriam Primary | 122 | 61.4 | 61.9% | 84.6% | 83.9% |
| Riverside Surgery | 107 | 84.9 | 71.6% | 79.8% | 82.0% |
| Whetstone Lane | 90 | 94.5 | 66.4% | 61.9% | 80.4% |
| St Catherine's | 124 | 72.0 | 46.2% | 56.1% | 80.0% |
| Devaney Med Ctr | 95 | 50.6 | 42.0% | 63.3% | 74.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of twenty-five measures trail national three-year change, led by routine reviews
Across 25 tracked measures, 19 trail England's three-year change. The widest lag is heart failure reviews, which fell 2.8% over three years while England rose +8.7% (an 11.51-point gap), although current coverage remains 81.8% against England's 78.5%. Psychosis alcohol recording fell 1.5 pp (England +5.4 pp) to 78.7% (England 81.8%). Conversely, statin therapy in diabetes without cardiovascular disease rose +3.8% (England +2.1%) to 77.3% (England 73.2%), and dementia prevalence increased +17.7% (England +6.0%), which may reflect lagging routine review recall alongside expanding prescribing and disease registers.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Alcohol record (psychosis)
Hypertension BP reading
BP control, 80+
COPD register
Diabetes statin (no CVD)
Cervical screening
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wirral (LAD) | Asset | PCN | Wirral (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 69 (2,168 beds) | n/a | Schools (catchment) | 106 | n/a |
| Children's centres | 9 | 16 | Places of worship | 91 | 171 |
| Libraries | 7 | 18 | Primary schools (LA maintained) | 28 | 52 |
| Primary academies | 17 | 36 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 65.0% (England 65.7%; 3-year change +2.8% vs England +4.4%) across 7,188 patients (7.8% prevalence), leaving a scale gap of 2,514 patients. For discussion: practices could run a single-template asthma review and inhaler check recall, offering after-school slots at high-concentration and high-volume Core20 surgeries. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster recall
In Q1 2025/26 (cohort 241), age-5 MMR2 is 87.6% (below the 95.0% target by 7.4 pp; below MMR1 at 92.5% by 4.9 pp) and 4-in-1 booster coverage is 83.8% (below 95.0% by 11.2 pp). Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Hypertension and SMI check recall
Hypertension control is 68.2% (England 70.3%) across 16,442 patients (16.7%; Wirral 18.0%, modelled gap range -1,537 to +1,204). SMI BP checks reach 82.0% (Wirral 85.6%) and BMI 77.4% (England 82.1%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Ethnicity recording and access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school MMR2 and booster recall (p12) | MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Hypertension and SMI check recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 · MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
